N@N

NEWARK, Del.--([ BUSINESS WIRE ])--[ SDIX ]a" (NASDAQ: SDIX), a leading supplier of rapid detection solutions to the $1 billion food pathogen testing market, today announced that its [ RapidChek CONFIRMa" non-O157 STEC Immunomagnetic Separation (IMS) ] test kit has been reviewed by the U.S. Department of Agriculture (USDA) and has been listed in the recently updated [ USDA Microbiological Laboratory Guidebook (MLG) 5B.02 ] as the IMS reagents to be used in E. coli testing.

On June 4, 2012, the USDA Food Safety Inspection Service (aFSISa) began monitoring of the aBig Sixa non-O157 shiga toxin producing E. coli (STEC), incorporating the RapidChek CONFIRMa"STEC test kit in their testing method. Recently, one of the Big Six, E.coli O145 has been implicated in an E.coli outbreak in the southern US, though the source has not been identified.

Tim Lawruk, Food Safety Marketing Director at SDIX, said, aOnce again SDIX has been able to apply its expertise in antibody development to validate six highly specific antibodies to address the new USDA regulation for monitoring non-O157 STEC in beef products. The decision by the USDA to incorporate our IMS product into their testing method over competitive offerings further validates the performance of SDIXas antibodies. Working with the USDA FSIS, we were able to quickly develop and validate these reagents to meet the marketas needs. We expect these reagents to be a valuable tool for the USDA, state and international regulatory agencies, and customers in the beef industry."

Continuing, Mr. Lawruk said, aThe MLG is considered the "gold standard guide" to testing methods by many in the food safety industry. Our listing in the MLG should provide testing labs confidence that deploying SDIXas confirmation reagents will ensure that they are complying with the testing requirements of the USDA. Based on customer requests for additional STEC testing tools, we will also be incorporating these antibodies into a RapidChek non-O157 test kit to be launched shortly, which includes multiplexed lateral flow test strips for the verification of aBig Sixa O-type. We expect these new IMS bead and test kit products to provide SDIX additional access to the estimated $57M E. coli testing market, which by some industry estimates, is expected to double over the next 3 years."

About SDIX([ www.sdix.com ])

SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.

In the life science market, SDIXas technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results.

This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like aanticipatea, acoulda, aenablea, aestimatea, aintenda, aexpecta, abelievea, acana, apotentiala, awilla, ashoulda, aprojecta, aplana and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.